Skip to main content
    S

    STAAR Surgical Company (STAA)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $26.01
    -0.38 (-1.44%)

    Market Cap: $1.32B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    STAAR Surgical Company (STAA) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Sep 30, 2026, STAAR Surgical Company reported EPS of $0.26, above the $0.05 estimate. It beat the EPS estimate in 6 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    79%(31/39)
    Avg Surprise
    +135.85%
    Streak
    3 Q

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus-$0.06
    Range-$0.13 - $0.00
    12 analysts
    Revenue Consensus
    $69.72M
    Range$62.25M - $79.10M
    12 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus$0.35
    Range$0.29 - $0.41
    3 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$0.29+18.7%
    60d ago$0.32+9.7%
    30d ago$0.37-6.3%
    7d ago$0.37-6.3%
    Current$0.35
    Revenue Consensus
    $101.58M
    Range$94.20M - $105.10M
    7 analysts

    Next Report

    STAA's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.

    STAA Earnings Call

    The latest STAA earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 39 quarters below that had an estimate, STAA beat 31, missed 3 and matched 5. Revenue for the quarter ended Sep 30, 2026 was $83.41M, down 11.9% from $94.73M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.26$0.05N/A+420.00%Beat-13.3%70 up, 1 downNov 4, 2026$83.41M
    Jun 30, 2026$0.18$0.05N/A+260.00%BeatN/A84 up, 0 downAug 12, 2026$93.53M
    Mar 31, 2026$0.29$0.08-$0.13 - $0.16+262.50%BeatN/A63 up, 1 downMay 13, 2026$93.52M
    Dec 31, 2025$0.01$0.15$0.06 - $0.28-94.78%MissN/A61 up, 1 downMar 3, 2026$57.80M
    Sep 30, 2025$0.30$0.05N/A+500.00%Beat+50.0%51 up, 1 downNov 5, 2025$94.73M
    Jun 30, 2025-$0.13-$0.56-$0.70 - -$0.39+76.79%Beat-133.3%71 up, 1 downAug 6, 2025$44.32M
    Mar 31, 2025-$1.00-$0.60-$0.78 - -$0.49-66.67%Miss-1009.1%100 up, 6 downMay 7, 2025$42.59M
    Dec 31, 2024-$0.69-$0.03-$0.13 - $0.10N/AN/A-531.3%82 up, 0 downFeb 11, 2025$48.95M
    Sep 30, 2024$0.20$0.18$0.09 - $0.21+11.11%Beat-33.3%80 up, 0 downOct 30, 2024$88.59M
    Jun 30, 2024$0.39$0.25$0.19 - $0.29+56.00%Beat-2.5%90 up, 0 downAug 7, 2024$99.00M
    Mar 31, 2024$0.11$0.06-$0.05 - $0.11+83.33%Beat-38.9%93 up, 0 downMay 7, 2024$77.36M
    Dec 31, 2023$0.16$0.17$0.06 - $0.30-5.88%Miss+14.3%100 up, 0 downFeb 26, 2024$76.27M
    Sep 30, 2023$0.30$0.18$0.11 - $0.26+66.67%Beat-18.9%100 up, 0 downNov 1, 2023$80.31M
    Jun 30, 2023$0.40$0.30N/A+33.33%Beat-4.8%112 up, 0 downAug 2, 2023$92.31M
    Mar 31, 2023$0.18$0.09-$0.03 - $0.18+100.00%Beat-37.9%110 up, 0 downMay 3, 2023$73.53M
    Dec 31, 2022$0.14$0.14$0.01 - $0.160.00%In line-26.3%100 up, 0 downFeb 21, 2023$64.04M
    Sep 30, 2022$0.37$0.21N/A+76.19%Beat+76.2%90 up, 0 downNov 2, 2022$76.05M
    Jun 30, 2022$0.42$0.23N/A+82.61%Beat+55.6%N/A0 up, 0 downAug 10, 2022$81.10M
    Mar 31, 2022$0.29$0.15N/A+93.33%Beat+45.0%80 up, 0 downMay 4, 2022$63.20M
    Dec 31, 2021$0.19$0.19N/A0.00%In line+35.7%70 up, 0 downFeb 23, 2022$59.00M
    Sep 30, 2021$0.21$0.17N/A+23.53%Beat+40.0%5N/ANov 3, 2021$58.35M
    Jun 30, 2021$0.27$0.09N/A+200.00%Beat+800.0%7N/AAug 4, 2021$62.37M
    Mar 31, 2021$0.20$0.03-$0.06 - $0.03+566.67%Beat+400.0%6N/AMay 5, 2021$50.75M
    Dec 31, 2020$0.14$0.14N/A0.00%In line+16.7%6N/AFeb 24, 2021$46.00M
    Sep 30, 2020$0.15$0.09N/A+66.67%Beat+25.0%6N/ANov 4, 2020$47.08M
    Jun 30, 2020$0.03$0.03N/A0.00%In line-78.6%6N/AAug 5, 2020$35.19M
    Mar 31, 2020$0.04$0.03N/A+33.33%Beat-55.6%5N/AMay 6, 2020$35.19M
    Dec 31, 2019$0.12$0.12N/A0.00%In line+71.4%5N/AFeb 26, 2020$38.88M
    Sep 30, 2019$0.12$0.08N/A+50.00%Beat+71.4%4N/AOct 30, 2019$39.05M
    Jun 30, 2019$0.14$0.10N/A+40.00%Beat+55.6%4N/AJul 31, 2019$39.66M
    Mar 31, 2019$0.09$0.05N/A+80.00%Beat+125.0%4N/AMay 1, 2019$32.58M
    Dec 31, 2018$0.07$0.02N/A+250.00%Beat+250.0%4N/AFeb 21, 2019$31.19M
    Sep 30, 2018$0.07-$0.03-$0.06 - -$0.02+333.33%Beat+75.0%5N/AOct 31, 2018$31.77M
    Jun 30, 2018$0.09$0.01-$0.02 - $0.01+800.00%BeatN/A5N/AAug 1, 2018$33.91M
    Mar 31, 2018$0.04-$0.04-$0.06 - -$0.02+200.00%BeatN/A5N/AMay 2, 2018$27.09M
    Dec 31, 2017$0.02-$0.01-$0.06 - $0.02+300.00%Beat0.0%5N/AFeb 28, 2018$24.85M
    Sep 30, 2017$0.04$0.02N/A+100.00%BeatN/A4N/ANov 8, 2017$23.47M
    Jun 30, 2017-$0.01-$0.03-$0.07 - -$0.03+66.67%BeatN/A4N/AAug 2, 2017$21.94M
    Mar 31, 2017-$0.04-$0.06N/A+33.33%BeatN/AN/AN/AMay 3, 2017$20.35M
    Dec 31, 2016$0.02-$0.02N/A+200.00%Beat+100.0%N/AN/AMar 2, 2017$22.14M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.82, after $0.01 the year before. It was -$0.03 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.82-8320.0%
    Dec 31, 2024$0.01-99.0%
    Dec 31, 2023$1.04-14.8%
    Dec 31, 2022$1.22+40.2%
    Dec 31, 2021$0.87+141.7%
    Dec 31, 2020$0.36-23.4%
    Dec 31, 2019$0.47+74.1%
    Dec 31, 2018$0.27+2600.0%
    Dec 31, 2017$0.01N/A
    Dec 31, 2016-$0.03N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,000 words across 11 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20267,01511
    2026Q2Jun 30, 20266,90212
    2026Q1Mar 31, 20266,28112
    2025Q4Dec 31, 20256,76312
    2025Q1Mar 31, 20258,69510
    2024Q4Dec 31, 202410,58715
    2024Q3Sep 30, 20244,0788
    2024Q2Jun 30, 20246,42011

    2026Q3 Earnings Call

    Opening remarks

    Connie Johnson Director of Investor Relations Thank you, operator. Good afternoon, and thank you for joining us. On the call today are Warren Foust, President and Chief Executive Officer of STAAR Surgical; and Deborah Andrews, Executive Vice President and Chief Financial Officer of STAAR Surgical. Earlier today, we reported our third quarter 2026 results. We posted our results release and shareholder letter to our investor website at investors.staar.com. Today's call is scheduled for 1 hour and will include Q&A for publishing analysts. We also invite webcast participants to send questions to ir@staar.com. Before we get started, during today's discussion, we will be making forward-looking statements. These statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Please read the disclosures in today's release and our SEC filings. Except as required by law, STAAR assumes no obligation to update these statements to reflect future events or actual outcomes. We will also reference certain non-GAAP financial measures, including adjusted EBITDA, adjusted EBITDA per diluted share, free cash flow, and results excluding the China deferred sales. Please refer to today's release for additional information and applicable reconciliations to the most directly comparable GAAP measures. Unless otherwise specified, all comparisons will be year-over-year. Finally, we intend to use our investor website to disclose material nonpublic information and comply with Regulation FD. Please monitor that website along with our press releases, SEC filings, and public calls and webcast. With that, I would like to turn the presentation over to Warren. Warren?

    Warren Foust President and Chief Executive Officer Thank you, Connie. Good afternoon, everyone, and thank you for joining us. At the start of the year, we set 3 goals: revenue growth, profit expansion, and innovation acceleration. Through the first 9 months, we've made progress on all 3. Year-to-date, we delivered record revenue, achieved strong profitability, and took important steps toward bringing our next generation of products to patients. Our strong cash flow and debt-free balance sheet give us flexibility to keep investing in that future. I want to thank our teams in China and Japan, our 2 largest markets, as well as all of our dedicated employees in Switzerland and the United States and all around the world. This year, they implemented a new ERP system, completed the move of China-bound ICL manufacturing to Switzerland, ramped production to support the EVO+ launch in China, and began the clinical trial process for 2 new lenses, all while continuing to serve surgeons and patients. That is a lot of change, and they have delivered and continue to do so, strengthening how we operate and laying further groundwork for future growth. Now let's talk about where we stand.

    Frequently Asked Questions About STAA

    Did STAA beat earnings estimates last quarter?

    Yes. STAAR Surgical Company reported EPS of $0.26 for the quarter ended Sep 30, 2026, above the $0.05 estimate, a 420.00% surprise.

    What EPS do analysts expect from STAA next quarter?

    The consensus EPS estimate for STAAR Surgical Company for the quarter ending Dec 31, 2026 is -$0.06 from 12 analysts, with estimates from -$0.13 to $0.00.

    How often does STAA beat earnings estimates?

    STAAR Surgical Company beat the EPS estimate in 6 of the 8 most recent quarters that had an estimate, with an average surprise of +171.12%.